Briya appoints CCO Jason Hein to bring ai-native evidence generation to global research organizations and life sciences. 14 Oct, 2026, 15:30 IDT Jason Hein joins as Chief Commercial Officer to scale AIRE, the scientific AI platform, as demand for AI-native evidence generation accelerates NEW YORK, Oct. 14, 2026 /PRNewswire/ - Briya, developer of AIRE, the scientific AI platform turning fragmented healthcare data into defensible evidence, today announced the appointment of Jason Hein as Chief Commercial Officer. The hire marks the beginning of a deliberate scale-up phase for the company, as Briya moves from proving AIRE's value with early research partners to expanding across the organizations that generate real-world evidence (RWE) for life sciences worldwide. Briya enters this phase as the RWE market confronts a widening analysis gap. Regulators and payers now demand continuous real-world proof, creating a growing divide between required evidence and the specialist scientific capacity available to generate it. Drugmakers must prove a product's real-world value repeatedly to win approval, expand labels, secure reimbursement, and satisfy post-market commitments, and must do so faster than ever. Biopharma now spends more than $25 billion a year generating that evidence, with more than two-thirds of it spent on expert analysis rather than on software or data. Because these complex studies depend on a limited pool of specialist scientists, team capacity cannot keep pace with demand. "Now more than ever, the constraint in evidence generation isn't a lack of scientific expertise. It's how much operational complexity we put around that expertise," said David Lazerson, CEO and Co-founder of Briya. "AIRE was built to change that and give researchers more room for science. We are pleased to welcome Jason, who deeply understands how research organizations scope, staff and deliver studies, and where the hours disappear. That combination of scientific workflow understanding and commercial experience will serve us and our customers as we continue to scale." AIRE handles much of the operational complexity between fragmented healthcare data and defensible evidence, managing everything from data preparation and harmonization through cohort building, analysis, validation and reporting, while researchers retain full control of the scientific methodology and interpretation. The result is increased research throughput with the expertise teams already have, giving scientists more room for science and greater capacity. No one feels that gain more acutely than the organizations whose business is research throughput. For CROs, HEOR consultancies and research institutes, the economics have long been set by the size and efficiency of their teams, which is why they are moving fastest from labor-based delivery to tech-enabled delivery, where capacity is determined by the strength of a team's tools. Briya is focused on these organizations first. They run the highest volume of studies, feel the capacity constraint most directly, and compete on turnaround and scientific depth in every proposal. Sponsors generating evidence in-house face the same constraint and adopt the same logic. In this role, Hein will lead Briya's global commercial strategy, overseeing everything from market positioning and growth through customer delivery and long-term client success. He joins from RTI International, where he served as Director of Corporate Development, leading equity investments and strategic partnerships across life sciences, pharma services, health data, and AI businesses, including RTI's collaboration with Navidence. He previously held commercial, corporate development and portfolio strategy roles at Codexis, where he helped commercialize the ECO Synthesis(R) platform for nucleic acid therapeutics, and at LGC Biosearch Technologies. He holds an MBA from the University of Minnesota Carlson School of Management and an MS in Molecular Biology from St. Cloud State University. "Research teams are being asked to deliver more ambitious studies on shorter timelines and tighter budgets," said Hein. "Regulators and payers want real patient evidence to demonstrate value at more points in a product's life. The pressure these structural market changes create can't be effectively solved by adding people to the problem. Technology that lets expert scientists take on more without sacrificing scientific rigor and trust must be part of the solution. That's what Briya AIRE is built for, and the market is ready for it." Briya AIRE is an AI-native research environment for clinical and real-world evidence generation. Unlike general-purpose AI research assistants, AIRE operates directly on patient-level data and carries a study from question to defensible result: cohort definition, data preparation and harmonization, analysis and documentation, with an auditable record of how each result was produced. AIRE draws rich clinical detail from both structured data and unstructured clinical notes, capturing evidence that structured fields alone miss. It is also built to work with any data source. Teams can use Briya's global network of 120 million patient records across four continents, their own internal data, public datasets, or third-party data they already license. Whatever the source, the division of labor stays the same: researchers keep full control of every scientific and methodological decision, and AIRE handles the operational work around it. For organizations delivering research to life sciences clients, that means more capacity per team, the ability to take on more complex projects, and a stronger offering in every proposal. About Briya Briya is the health AI company behind AIRE, a scientific AI platform built to expand research capacity and deliver better evidence. AIRE handles the operational complexity between fragmented data and defensible evidence, while preserving scientific rigor and keeping researchers in control. Combining scientific AI, NLP, and no-code advanced analytics with secure access to a global real-world data network, AIRE gives researchers across life sciences, healthcare, and service firms more room for science. Visit www.briya.com. SOURCE Briya

Briya, developer of the scientific AI platform AIRE, has appointed Jason Hein as chief commercial officer. The New York company said the hire starts a scaleup phase, as it moves from early research partners to wider expansion among organisations that generate real-world evidence for life sciences. Hein will lead global commercial strategy. He joins from RTI International, where he was director of corporate development, and previously worked at Codexis and LGC Biosearch Technologies. Briya says regulators and payers now demand continuous real-world proof, yet specialist scientists are in short supply. Biopharma spends more than $25 billion a year on such evidence, with over two-thirds going to expert analysis. AIRE automates data preparation, cohort building, analysis and reporting while researchers keep control of the science. It can draw on Briya's network of 120 million patient records across four continents.

New study shows Briya's AIRE AI research platform expands steatotic liver disease identification by 360% using previously overlooked radiology data. 08 Oct, 2026, 15:30 IDT Briya AIRE's analysis of 28,795 abdominal ultrasound reports found 78% of steatotic liver patients were identified only through unstructured radiology reports NEW YORK, Oct. 8, 2026 /PRNewswire/ - Briya, the health AI company redefining healthcare research with AIRE, a trusted AI platform, today announced results from a real-world study demonstrating how AI and natural language processing (NLP) can uncover under-documented cases of metabolic dysfunction-associated steatotic liver disease (MASLD) from unstructured radiology reports. Using AIRE, researchers identified 360% more steatotic liver patients than structured data alone revealed. The technology then enabled risk stratification for patients at risk of progression, creating opportunities to intervene before the disease becomes irreversible, with the potential to save lives. The study demonstrates how healthcare organizations, pharma companies and research and consulting firms can use existing routine data to identify overlooked patients, strengthen risk stratification and generate real-world evidence without additional diagnostic procedures or burden on clinical workflows. "Briya AIRE fundamentally changed how we were able to identify patients for this study," said Gadi Lalazar, MD, Head of the Liver Unit at Shaare Zedek Medical Center. "Many of these patients may not have known they had steatotic liver disease because the finding was buried in an ultrasound report performed for some other reason. Identifying them earlier creates an opportunity for physicians to initiate treatment before the disease progresses to more serious and potentially irreversible stages." The findings demonstrate how unlocking information from unstructured radiology reports gives researchers access to larger, more representative patient populations without requiring additional data collection. The study, titled "Leveraging Real-World Data and NLP to Identify At Risk Metabolic Dysfunction Associated Steatohepatitis in the General Population," will be presented at AASLD's The Liver Meeting 2026 by Dr. Or Shaked, Director of Medical Research Solutions at Briya, on November 6 at 1:00 PM MT during the "MASLD/MASH - Epidemiology and Natural History, Prevention and Outcomes" session. (Abstract 2476) The study analyzed 28,795 abdominal ultrasound reports from 20,422 unique patients between 2020 and 2024 and identified an additional 4,036 patients with a steatotic liver. This expanded the relevant study population by 360%, from 1,122 to 5,158 patients. The findings revealed a major gap when looking at structured records or diagnostic codes alone. Only 22% of identified steatotic liver patients had a documented diagnosis in structured EHR fields, while 78% were identified exclusively through Briya AIRE's NLP analysis of unstructured ultrasound data. External expert validation found 94% precision and 97% recall for steatotic liver detection. With a more complete study population, researchers then assessed the risk of disease progression using existing laboratory data and ultrasound reports. The analysis identified 4,368 patients whose FIB-4 scores placed them above the conventional at-risk threshold. "AIRE's specialized research agents were used to extract information from unstructured fields, harmonize it with existing structured data and build the study population," said Dr. Or Shaked of Briya. "The goal is to take on more of the complex data preparation work so researchers can use more of the available information and focus on answering scientific questions that can ultimately influence care." AIRE enabled the researchers to extract clinically relevant information from tens of thousands of radiology reports and incorporate it into the study population alongside existing clinical and laboratory data. Doing this manually would have required extensive review and data preparation, making it difficult to apply consistently at scale. By automating much of that labor-intensive work, AIRE significantly accelerated the research timeline. About Briya Briya is the health AI company behind AIRE, a scientific AI platform built to expand research capacity and deliver better evidence. AIRE handles the operational complexity between fragmented data and defensible evidence, while preserving scientific rigor and keeping researchers in control. Combining scientific AI, NLP and no-code advanced analytics with secure access to a global real-world data network, AIRE gives researchers across life sciences, healthcare and service firms more room for science. Media Contact: SOURCE Briya